Beijing Center for Disease Prevention and Control
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 76,220
- Locations
- 11
- Primary Endpoint
- Average rate of chronic hepatitis B accepting antiviral treatment
Study Overview
Brief Summary
Through two-stage stratified cluster sampling, investigators studied the antiviral treatment rate and the main factors affecting the antiviral treatment in community chronic HBV infection-related liver disease population.
Detailed Description
Hepatitis B virus (HBV) infection is a major public health problem worldwide. China has the world's largest burden of HBV infection and will be a major contributor towards the global elimination of hepatitis B disease by 2030. While, the antiviral treatment rate and the main factors affecting the antiviral treatment in community chronic HBV infections is still unknown. In response to the above situation, Sampling applied a two-stage stratified cluster sampling design in 16 Districts and 331 Townships. Investigators wanted to know the one who is eligible for treated criteria based on community in 25 and over years old in Beijing.
Study Design
- Study Type
- Observational
- Observational Model
- Ecologic Or Community
- Time Perspective
- Cross Sectional
Eligibility Criteria
- Ages
- 25 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •older than 25 years old;
- •Residents with medical insurance coverage lived in Beijing more than 6 months .
Exclusion Criteria
- •Persons with pacemakers;
- •Pregnant women;
- •Persons with ascites;
- •The one whose wound was not cured at the right upper abdomen
Outcomes
Primary Outcomes
Average rate of chronic hepatitis B accepting antiviral treatment
Time Frame: Baseline
The one who is eligible for HBV treated criteria based on community in 25 and over years old in Beijing.
HBsAg positive rate
Time Frame: Baseline
Complete HBsAg tests for more than 60,000 people over the age of 25 in Beijing
Secondary Outcomes
No secondary outcomes reported
Investigators
Wu Jiang
Director of institue for immunization and prevention of Beijing CDC
Centers for Disease Control and Prevention, China